Diplomat Partners With CSI Specialty Group to Expand Health System Services

FLINT, Mich., Jan. 7, 2019 /PRNewswire/ -- Diplomat Pharmacy, Inc. (NYSE: DPLO), and CSI Specialty Group, a globally recognized specialty pharmacy consulting firm, have launched a program for hospitals and health systems interested in starting or expanding their own specialty pharmacy services to benefit from Diplomat's limited-distribution drug portfolio and expertise treating rare, chronic, and complex diseases.

CSI, a partner of leading national healthcare solutions organization and Intermountain Healthcare company Intalere, offers specialty pharmacy solutions to help health systems improve patient care and optimize access to specialty medications.

Robyn Peters, executive vice president of sales and payer strategies at Diplomat, said the program is designed to address barriers to effective care and increase coordination across the healthcare team.

"We are proud to partner with CSI to provide access to a suite of cost-effective specialty pharmacy services for their hospital members," Peters said. "Diplomat's supportive care model offers a unique solution for oncology care management, access to limited-distribution drugs and 340B contract-pharmacy support."

CSI President and CEO Suzette DiMascio commented, "This partnership has the power to enhance patient care by combining our consultative solutions for health systems with Diplomat's extensive specialty pharmacy capabilities. Together, we're optimizing specialty pharmacy services for patients by offering tailored solutions that will deliver lasting financial, operational, and clinical performance excellence."

To learn more about Diplomat, visit diplomat.is.

Forward-Looking Statements

This press release contains forward-looking statements made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. Forward-looking statements give current expectations or forecasts of future events or our future financial or operating performance, including potential support services to be provided by Diplomat to the hospital, health system and 340B contract-pharmacy members and clients of CSI (and any implied financial impact). The forward-looking statements contained in this press release are based on management's good-faith belief and reasonable judgment based on current information. These statements are qualified by important risks and uncertainties, many of which are beyond our control, that could cause our actual results to differ materially from those forecasted or indicated by such forward-looking statements. These risks include the unknown number of entities and volume of services to be provided pursuant to the CSI partnership and the timing and profitability of such services; our ability to adapt to changes or trends within the specialty pharmacy industry; our relationships with wholesalers and key pharmaceutical manufacturers; our ability to expand the number of specialty drugs we dispense and related services; maintaining existing patients; bad publicity about, or market withdrawal of, specialty drugs we dispense; our failure to maintain significant relationships or build new relationships with clinical experts and key thought leaders; complying with complex and evolving requirements and changes in state and federal government regulations, including Medicare and Medicaid; increased scrutiny and the publication of proposed regulatory guidance or future changes to the 340B Program; entry into disadvantageous contracts; and the additional factors set forth in  "Risk Factors" in Diplomat's Annual Report on Form 10-K for the year ended Dec. 31, 2017, and in subsequent reports filed with or furnished to the Securities and Exchange Commission. Except as may be required by any applicable laws, Diplomat assumes no obligation to publicly update such forward-looking statements, which are made as of the date hereof or the earlier date specified herein, whether as a result of new information, future developments, or otherwise.

About Diplomat

Diplomat (NYSE: DPLO) is the nation's largest independent provider of specialty pharmacy and infusion services. Diplomat helps people with complex and chronic health conditions in all 50 states, partnering with payers, providers, hospitals, manufacturers, and more. Rooted in this patient care expertise, Diplomat also serves payers through CastiaRx, a leading specialty benefit manager, and offers tailored solutions for healthcare innovators through EnvoyHealth. Diplomat opened its doors in 1975 as a neighborhood pharmacy with one essential tenet: "Take good care of patients and the rest falls into place." Today, that tradition continues — always focused on improving patient care. For more information, visit diplomat.is.

About CSI Specialty Group

Named as one of Consulting Magazine's Fastest Growing Firms, CSI Specialty Group is a globally recognized, Leadership Consulting Firm dedicated to providing solutions that continually elevate the specialty pharmacy industry. By providing inventive consulting, workforce planning & talent acquisition solutions, they uniquely tailor service offerings to help clients drive sustainable, accelerated growth. As the provider of the industry's first dedicated podcast for specialty pharmacy, CSI is at the forefront of pioneering innovative concepts to meet the changing needs of specialty pharmacy, home infusion, mail order/PBM, health systems and pharma/biotech clients across the USA and throughout Europe. For more information about CSI Specialty Group, visit http://www.CSIgroup.net.

CONTACT:
Terri Anne Powers, Vice President of Investor Relations
312.889.5244 | [email protected]

Elizabeth Carr, Corporate Communications Manager
810.768.9871 | [email protected]

SOURCE Diplomat Pharmacy, Inc.

Related Links

http://www.diplomat.is